FDA approved drugs:
| # |
|
Drug Name |
Active Ingredient(s) 18
|
Company |
Approval Date |
| 1 |
|
Doxil
18
49
|
DOXORUBICIN HYDROCHLORIDE |
Alza |
June 1999 |
Disease/s that Drug Treats:ovarian cancer that is refractory to other first-line therapies
Indications and Usage:
18
DOXIL is an anthracycline topoisomerase II inhibitor indicated for: Ovarian cancer (1.1)After failure of platinum-based chemotherapy. AIDS-related Kaposiâs Sarcoma (1.2)After failure of prior systemic chemotherapy or intolerance to such therapy. Multiple Myeloma (1.3)In combination with bortezomib in patients who have not previouslyreceived bortezomib and have received at least one prior therapy.
DrugBank Targets:
16
1. DNA;2. DNA topoisomerase 2-alpha
Mechanism of Action:
18
Target: nucleic acidsynthesis
Action: inhibitor
FDA: The active ingredient of DOXIL is doxorubicin HCl. The mechanism of action ofdoxorubicin HCl is thought to be related to its ability to bind DNA and inhibit nucleic acidsynthesis. Cell structure studies have demonstrated rapid cell penetration and perinuclearReference ID: 373359617 chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, andinduction of mutagenesis and chromosomal aberrations.
|
| 2 |
|
Fusilev
18
|
LEVOLEUCOVORIN CALCIUM |
Spectrum Pharmaceuticals |
March of 2008 |
Disease/s that Drug Treats:rescue after high-dose methotrexate therapy in osteosarcoma and to reduce the toxicity of methotrexate
Indications and Usage:
18
Fusilev is a folate analog indicated for: Rescue after high-dose methotrexate therapy in osteosarcoma. Diminishing the toxicity and counteracting the effects of impairedmethotrexate elimination and of inadvertent overdosage of folic acidantagonists. Use in combination chemotherapy with 5-fluorouracil in the palliativetreatment of patients with advanced metastatic colorectal cancer.(1)Limitations of UseFusilev is not approved for pernicious anemia and megaloblastic anemias.Improper use may cause a hematologic remission while neurologicmanifestations continue to progress. (1.1)
DrugBank Targets:
16
1. Thymidylate synthase
Mechanism of Action:
18
Target: therapeutic and toxic effects of folic acidantagonists / therapeutic and toxic effects of fluoropyrimidines used in cancer therapy
Action: counteract/enhance
FDA: 12.1.1 Levoleucovorin effects during high-dose methotrexate therapyLevoleucovorin is the pharmacologically active isomer of 5-formyl tetrahydrofolic acid. Levoleucovorin does not requirereduction by the enzyme dihydrofolate reductase in order to participate in reactions utilizing folates as a source of âonecarbonâmoieties. Administration of levoleucovorin can counteract the therapeutic and toxic effects of folic acidantagonists such as methotrexate, which act by inhibiting dihydrofolate reductase.12.1.2 Levoleucovorin effects in combination with 5-fluorouracilLevoleucovorin can enhance the therapeutic and toxic effects of fluoropyrimidines used in cancer therapy such as5-fluorouracil. 5-fluorouracil is metabolized to 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), which binds to andinhibits thymidylate synthase (an enzyme important in DNA repair and replication). Levoleucovorin is readily convertedto another reduced folate, 5,10-methylenetetrahydrofolate, which acts to stabilize the binding of FdUMP to thymidylatesynthase and thereby enhances the inhibition of this enzyme.
|
| 3 |
|
Intron A
18
49
|
INTERFERON ALFA-2B |
Schering-Plough |
December 1997/ December 1995/ March 1997 |
Disease/s that Drug Treats:non-Hodgkin's lymphoma/ malignant melanoma / Hepatitis C
Indications and Usage:
18
Hairy Cell Leukemia INTRON® A is indicated for the treatment of patients 18 years ofage or older with hairy cell leukemia.Malignant Melanoma INTRON A is indicated as adjuvant to surgical treatment inpatients 18 years of age or older with malignant melanoma who are free of disease butat high risk for systemic recurrence, within 56 days of surgery.Follicular Lymphoma INTRON A is indicated for the initial treatment of clinicallyaggressive (see Clinical Pharmacology) follicular Non-Hodgkinâs Lymphoma inconjunction with anthracycline-containing combination chemotherapy in patients 18years of age or older. Efficacy of INTRON A therapy in patients with low-grade, lowtumorburden follicular Non-Hodgkinâs Lymphoma has not been demonstrated.Condylomata Acuminata INTRON A is indicated for intralesional treatment of selectedpatients 18 years of age or older with condylomata acuminata involving externalsurfaces of the genital and perianal areas (see DOSAGE AND ADMINISTRATION).The use of this product in adolescents has not been studied.AIDS-Related Kaposi's Sarcoma INTRON A is indicated for the treatment of selectedpatients 18 years of age or older with AIDS-Related Kaposi's Sarcoma. The likelihoodof response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited lymphadenopathy and who have a relatively intact immunesystem as indicated by total CD4 count.Chronic Hepatitis C INTRON A is indicated for the treatment of chronic hepatitis C inpatients 18 years of age or older with compensated liver disease who have a history ofblood or blood-product exposure and/or are HCV antibody positive. Studies in thesepatients demonstrated that INTRON A therapy can produce clinically meaningful effectson this disease, manifested by normalization of serum alanine aminotransferase (ALT)and reduction in liver necrosis and degeneration.A liver biopsy should be performed to establish the diagnosis of chronic hepatitis.Patients should be tested for the presence of antibody to HCV. Patients with othercauses of chronic hepatitis, including autoimmune hepatitis, should be excluded. Priorto initiation of INTRON A therapy, the physician should establish that the patient hascompensated liver disease. The following patient entrance criteria for compensated liverdisease were used in the clinical studies and should be considered before INTRON Atreatment of patients with chronic hepatitis C: No history of hepatic encephalopathy, variceal bleeding, ascites, or otherclinical signs of decompensation Bilirubin Less than or equal to 2 mg/dL Albumin Stable and within normal limits Prothrombin Time Less than 3 seconds prolonged WBC Greater than or equal to 3000/mm3 Platelets Greater than or equal to 70,000/mm3Serum creatinine should be normal or near normal.Prior to initiation of INTRON A therapy, CBC and platelet counts should beevaluated in order to establish baselines for monitoring potential toxicity. These testsshould be repeated at Weeks 1 and 2 following initiation of INTRON A therapy, andmonthly thereafter. Serum ALT should be evaluated at approximately 3-month intervalsto assess response to treatment (see DOSAGE AND ADMINISTRATION).Patients with preexisting thyroid abnormalities may be treated if thyroidstimulatinghormone (TSH) levels can be maintained in the normal range by medication.TSH levels must be within normal limits upon initiation of INTRON A treatment and TSHtesting should be repeated at 3 and 6 months (see PRECAUTIONS, LaboratoryTests).INTRON A in combination with REBETOL® is indicated for the treatment ofchronic hepatitis C in patients 3 years of age and older with compensated liver diseasepreviously untreated with alpha interferon therapy and in patients 18 years of age andolder who have relapsed following alpha interferon therapy. See REBETOL prescribinginformation for additional information. Chronic Hepatitis B INTRON A is indicated for the treatment of chronic hepatitis B inpatients 1 year of age or older with compensated liver disease. Patients who have beenserum HBsAg positive for at least 6 months and have evidence of HBV replication(serum HBeAg positive) with elevated serum ALT are candidates for treatment. Studiesin these patients demonstrated that INTRON A therapy can produce virologic remissionof this disease (loss of serum HBeAg) and normalization of serum aminotransferases.INTRON A therapy resulted in the loss of serum HBsAg in some responding patients.Prior to initiation of INTRON A therapy, it is recommended that a liver biopsy beperformed to establish the presence of chronic hepatitis and the extent of liver damage.The physician should establish that the patient has compensated liver disease. Thefollowing patient entrance criteria for compensated liver disease were used in theclinical studies and should be considered before INTRON A treatment of patients withchronic hepatitis B: No history of hepatic encephalopathy, variceal bleeding, ascites, or othersigns of clinical decompensation Bilirubin Normal Albumin Stable and within normal limits Prothrombin Time Adults less than 3 seconds prolongedPediatrics less than or equal to 2 seconds prolonged WBC Greater than or equal to 4000/mm3 Platelets Adults greater than or equal to 100,000/mm3Pediatrics greater than or equal to 150,000/mm3Patients with causes of chronic hepatitis other than chronic hepatitis B or chronichepatitis C should not be treated with INTRON A. CBC and platelet counts should beevaluated prior to initiation of INTRON A therapy in order to establish baselines formonitoring potential toxicity. These tests should be repeated at treatment Weeks 1, 2,4, 8, 12, and 16. Liver function tests, including serum ALT, albumin, and bilirubin,should be evaluated at treatment Weeks 1, 2, 4, 8, 12, and 16. HBeAg, HBsAg, andALT should be evaluated at the end of therapy, as well as 3- and 6-months posttherapy,since patients may become virologic responders during the 6-month periodfollowing the end of treatment. In clinical studies in adults, 39% (15/38) of respondingpatients lost HBeAg 1 to 6 months following the end of INTRON A therapy. Ofresponding patients who lost HBsAg, 58% (7/12) did so 1 to 6 months post-treatment.A transient increase in ALT greater than or equal to 2 times baseline value (flare)can occur during INTRON A therapy for chronic hepatitis B. In clinical trials in adultsand pediatrics, this flare generally occurred 8 to 12 weeks after initiation of therapy andwas more frequent in responders (adults 63%, 24/38; pediatrics 59%, 10/17) than innonresponders (adults 27%, 13/48; pediatrics 35%, 19/55). However, in adults andpediatrics, elevations in bilirubin greater than or equal to 3 mg/dL (greater than or equalto 2 times ULN) occurred infrequently (adults 2%, 2/86; pediatrics 3%, 2/72) duringtherapy. When ALT flare occurs, in general, INTRON A therapy should be continued unless signs and symptoms of liver failure are observed. During ALT flare, clinicalsymptomatology and liver function tests including ALT, prothrombin time, alkalinephosphatase, albumin, and bilirubin, should be monitored at approximately 2-weekintervals (see WARNINGS).
DrugBank Targets:
16
1. Interferon alpha/beta receptor 2;2. Interferon alpha/beta receptor 1
Mechanism of Action:
18
Target: intracellular oncogene expression, natural killer and cytotoxic T-cells, microphage, cytokine production
Action: stimulation, induction (unspecified effects on oncogene expression)
FDA: -
|
| 4 |
|
Taxol
18
49
|
PACLITAXEL |
Bristol-Myers Squibb |
August 1997 |
Disease/s that Drug Treats:Kaposi's Sarcoma
Indications and Usage:
18
Paclitaxel Injection, USP is indicated as subsequent therapy for the treatment of advanced carcinoma ofthe ovary. As first-line therapy, Paclitaxel Injection, USP is indicated in combination with cisplatin.Paclitaxel Injection, USP is indicated for the adjuvant treatment of node-positive breast canceradministered sequentially to standard doxorubicin-containing combination chemotherapy.. In the clinicaltrial, there was an overall favorable effect on disease-free and overall survival in the total population ofpatients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen andprogesterone receptor-negative tumors (see CLINICAL STUDIES, Breast Carcinoma).Paclitaxel Injection, USP is indicated for the treatment of breast cancer after failure of combinationchemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapyshould have included an anthracycline unless clinically contraindicated.Paclitaxel Injection, USP, in combination with cisplatin, is indicated for the first-line treatment of nonsmallcell lung cancer in patients who are not candidates for potentially curative surgery and/or radiationtherapy.Paclitaxel Injection, USP is indicated for the second-line treatment of AIDS-related Kaposiâs sarcoma.
DrugBank Targets:
16
1. Apoptosis regulator Bcl-2;2. Tubulin beta-1 chain;3. Nuclear receptor subfamily 1 group I member 2;4. Microtubule-associated protein 4;5. Microtubule-associated protein 2;6. Microtubule-associated protein tau
Mechanism of Action:
18
Target: microtubules
Action: promoter of assembly & preventor of depolymerization
FDA: Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulindimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibitionof the normal dynamic reorganization of the microtubule network that is essential for vital interphase andmitotic cellular functions. In addition, paclitaxel induces abnormal arrays or âbundlesâ of microtubulesthroughout the cell cycle and multiple asters of microtubules during mitosis.Following intravenous administration of paclitaxel, paclitaxel plasma concentrations declined in abiphasic manner. The initial rapid decline represents distribution to the peripheral compartment andelimination of the drug. The later phase is due, in part, to a relatively slow efflux of paclitaxel from theperipheral compartment.Pharmacokinetic parameters of paclitaxel following 3- and 24-hour infusions of paclitaxel at dose levelsof 135 and 175 mg/m2 were determined in a Phase 3 randomized study in ovarian cancer patients and aresummarized in the following table:
|
| 5 |
|
Votrient
18
49
|
PAZOPANIB HYDROCHLORIDE |
GlaxoSmithKline |
April 2012/ October of 2009 |
Disease/s that Drug Treats:soft tissue sarcoma/ renal cell carcinoma
Indications and Usage:
18
VOTRIENT is a kinase inhibitor indicated for the treatment of patients with: advanced renal cell carcinoma. (1) advanced soft tissue sarcoma who have received prior chemotherapy. (1)Limitation of Use: The efficacy of VOTRIENT for the treatment of patientswith adipocytic soft tissue sarcoma or gastrointestinal stromal tu mors has notbeen demonstrated.
DrugBank Targets:
16
1. Vascular endothelial growth factor receptor 1;2. Vascular endothelial growth factor receptor 2;3. Vascular endothelial growth factor receptor 3;4. Platelet-derived growth factor receptor alpha;5. Platelet-derived growth factor receptor beta;6. Mast/stem cell growth factor receptor Kit;7. Fibroblast growth factor receptor 3;8. Tyrosine-protein kinase ITK/TSK;9. Fibroblast growth factor 1;10. SH2B adapter protein 3
Mechanism of Action:
18
Target: vascular epidermal growth factor receptor (VEGFR) tyrosine kinase
Action: inhibitor
FDA: Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factorreceptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-αand -β, fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2receptor-inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), andtransmembrane glycoprotein receptor tyrosine kinase (c-Fms). In vitro, pazopanib inhibitedligand-induced autophosphorylation of VEGFR-2, Kit, and PDGFR-β receptors. In vivo,pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis ina mouse model, and the growth of some human tumor xenografts in mice.
|
Drugs for Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 647)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Doxorubicin |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
23214-92-8 |
31703
|
|
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-hydroxydaunomycin
14-Hydroxydaunomycin
14-hydroxydaunorubicine
14-Hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
adiblastine (hydrochloride salt)
ADM
ADR
adr iablatina (hydrochloride salt)
Adriablastin
Adriablastine
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin semiquinone
Adriamycin Semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (hydrochloride salt)
Adriblastina (TN)
Adriblastine
adriblatina (hydrochloride salt)
Adrimedac
Aerosolized Doxorubicin
Baxter brand OF doxorubicin hydrochloride
Bedford brand OF doxorubicin hydrochloride
BPBio1_000502
BRD-K92093830-003-04-3
Bristol-myers squibb brand OF doxorubicin hydrochloride
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
Caelyx
CCRIS 739
Cell pharm brand OF doxorubicin hydrochloride
CHEBI:28748
CHEMBL179
CID31703
Columbia brand OF doxorubicin hydrochloride
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
Doxil
Doxo
doxo Cell
doxo-Cell
Doxolem
doxorubicin
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin HCl
|
Doxorubicin hexal
Doxorubicin hydrochloride
Doxorubicin Hydrochloride
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin NC
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicina ferrer farm
Doxorubicina funk
Doxorubicina tedec
Doxorubicine
Doxorubicine [INN-French]
Doxorubicine baxter
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicinum
Doxorubicinum [INN-Latin]
Doxotec
DOX-SL
EINECS 245-495-6
Elan brand OF doxorubicin hydrochloride
Farmablastina (hydrochloride salt)
Farmiblastina
Ferrer brand OF doxorubicin hydrochloride
FI 106
Hexal brand OF doxorubicin hydrochloride
HMS2089H06
HSDB 3070
Hydrochloride, doxorubicin
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
Kenfarma brand OF doxorubicin hydrochloride
Lemery brand OF doxorubicin hydrochloride
LMPK13050001
LS-1029
LS-165655
Medac brand OF doxorubicin hydrochloride
MLS000759533
Myocet
NChemBio.2007.10-comp13
nchembio809-comp5
NCI-C01514
NDC 38242-874
Neocorp brand OF doxorubicin hydrochloride
NIOSH/JT9100000
NSC 123127
Onkodox
Onkoworks brand OF doxorubicin hydrochloride
Pfizer brand OF doxorubicin hydrochloride
Prasfarma brand OF doxorubicin hydrochloride
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Ribodoxo
Ribosepharm brand OF doxorubicin hydrochloride
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
Tedec meiji brand OF doxorubicin hydrochloride
ThermoDox
TLC D-99
Triferric doxorubicin
UNII-80168379AG
Urokit doxo cell
Urokit doxo-cell
|
|
| 2 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
6055-19-2, 50-18-0 |
2907
|
|
Synonyms:
(-)-Cyclophosphamide
(+-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
ASTA B518
B 518
B-518
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
BRN 0011744
BSPBio_002099
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
CID2907
Clafen
Claphene
CP
CPA
CTX
CY
Cycloblastin
Cyclophosphamid
cyclophosphamide
Cyclophosphamide
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (+-)-Isomer
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
|
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
DivK1c_000246
EINECS 200-015-4
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
EU-0100238
Genoxal
Hexadrin
HMS2090A12
HSDB 3047
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
Ledoxina
Lopac0_000238
Lopac-C-0768
LS-1302
LS-99787
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI60_002097
NCI-C04900
Neosar
NINDS_000246
NSC 26271
NSC26271
NSC-26271
NSC273033
NSC273034
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra waste number U058
Rcra Waste Number U058
Revimmune
S1217_Selleck
Semdoxan
Sendoxan
Senduxan
SK 20501
SPBio_001071
Spectrum_000858
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
STK177249
STOCK2S-91217
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
|
|
| 3 |
|
Vincristine |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
57-22-7, 2068-78-2 |
5978
|
|
Synonyms:
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
Cellcristin
CHEBI:28445
CID5978
Citomid
D08679
DB00541
EINECS 200-318-1
Farmistin
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
LS-228
Marqibo
NCGC00163700-01
NCI60_026703
NCI-C04864
NSC-67574
Onco TCS
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
Onkocristin
|
PFS, Vincasar
Sulfate, vincristine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristin bristol
Vincristin medac
Vincristina
Vincristina [DCIT]
vincristine
Vincristine (INN)
Vincristine [INN:BAN]
Vincristine sulfate
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristinum
Vincristinum [INN-Latin]
Vincrisul
Vincrstine
Vincrystine
Vinkristin
Vintec
Z-D-Val-lys(Z)-OH
Z-D-Val-Lys(Z)-OH
|
|
| 4 |
|
Bleomycin |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1 |
|
11056-06-7 |
5360373
|
|
Synonyms:
(betaR)-N(alpha)-{[6-amino-2-((1S)-3-amino-1-{[(2S)-2,3-diamino-3-oxopropyl]amino}-3-oxopropyl)-5-methylpyrimidin-4-yl]carbonyl}-beta-{2-O-[3-O-(aminocarbonyl)-alpha-D-mannopyranosyl]-alpha-L-gulopyranosyloxy}-N-[(1R,2S,3S)-5-({(1S,2R)-1-[({2-[4-({[3-(dimethylsulfonio)propyl]amino}carbonyl)-2,4'-bi-1,3-thiazol-2'-yl]ethyl}amino)carbonyl]-2-hydroxypropyl}amino)-3-hydroxy-4-methyl-5-oxopentan-2-yl]-L-histidinamide
11056-06-7
11116-31-7
1400-95-9
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
37208-04-1
37293-16-6
37353-43-8
9041-93-4
9041-93-4 (sulfate (salt))
AC1L9UFF
AC1NSEJD
AC1NUTOQ
Almirall brand OF bleomycin sulfate
Bellon brand OF bleomycin sulfate
Bellon, bléomycine
Blanoxan
Blenoxane
Bleo
bleo Cell
bleo-Cell
BLEOcell
Bleocin
Bleogin
Bleolem
Bleomicin
Bleomicina
Bleomicina [INN-Spanish]
bleomycin
Bleomycin a(2)
Bleomycin A(2)
bleomycin a2
Bleomycin a2
Bleomycin A2
Bleomycin A2 & Bleomycin B2.
Bleomycin b(2)
Bleomycin B(2)
Bleomycin b2
Bleomycin B2
Bleomycin sulfate
Bleomycin sulphate
|
Bleomycine
Bleomycine [INN-French]
Bléomycine bellon
Bleomycins
Bleomycinum
Bleomycinum [INN-Latin]
Bleomycinum mack
BLM
Bristol myers squibb brand OF bleomycin sulfate
Bristol-myers squibb brand OF bleomycin sulfate
Bull brand OF bleomycin sulfate
C06854
C55H85N17O21S3
C55H86N17O21S3
CCRIS 2754
Cell pharm brand OF bleomycin sulfate
CHEBI:3139
CHEMBL403664
CID456190
CID5360373
CID5460769
DB00290
EINECS 234-356-5
HSDB 3208
Lemery brand OF bleomycin sulfate
LMPK14000006
LS-44860
LS-524
Lundbeck brand OF bleomycin sulfate
Mack brand OF bleomycin sulfate
Mack, bleomycinum
N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide
N1-(3-(Dimethylsulfonio)propyl)bleomycinamide
NDC 0015-3010
NSC 125066
Pingyangmyvin A2
STOCK1N-74760
Sulfate, bleomycin
UNII-13M89UEA7W
UNII-40S1VHN69B
Zhengguangmycin A2
Zhengguangmycin A2 [Chinese]
|
|
| 5 |
|
Ritonavir |
Approved, Investigational |
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable |
|
155213-67-5 |
392622
|
|
Synonyms:
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
155213-67-5
1hxw
1sh9
538, ABT
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
A-84538
Abbott 84538
ABBOTT-84538
ABT 538
ABT 84538
ABT538
ABT-538
AC1L94GB
AC-733
AKOS000280930
BIDD:GT0387
BIDD:PXR0023
Bio-0093
C07240
C37H48N6O5S2
CHEBI:45409
CHEMBL163
CID392622
CPD000466395
D00427
D019438
DB00503
|
DRG-0244
FT-0082824
HMS2051B08
HSDB 7160
LS-148860
MLS000759541
MLS001424063
MolPort-000-883-877
N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide
NCGC00159462-02
Norvir
Norvir (TM)
Norvir (TN)
Norvir Sec
NSC693184
RIT
ritonavir
Ritonavir
Ritonavir (JAN/USAN/INN)
Ritonavir [USAN]
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.
Ritonavirum
RTV
S1185_Selleck
SAM001246783
SMR000466395
STK634209
ZINC03944422
|
|
| 6 |
|
Efavirenz |
Approved, Investigational |
Phase 4,Phase 3,Not Applicable |
|
154598-52-4 |
64139
|
|
Synonyms:
(-)-6-chloro-4-CYCLOPROPYLETHYNYL-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
(-)-6-CHLORO-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
(-)-Efavirenz
(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one
(4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one
(4S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
(S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-ben
(S)-6-chloro-4-(Cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(S)-6-chloro-4-Cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
(S)-6-chloro-4-Cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[D][1,3]oxazin-2-one
(S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
154598-52-4
1ikv
1ikw
2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)- (9
6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one
6-chloro-4-(2-Cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[D][1,3]oxazin-2-one
AC-19049
AC1L20IX
BIDD:GT0383
Bristol-myers squibb brand OF efavirenz
C08088
C14H9ClF3NO2
CHEBI:119486
CHEMBL223228
CID64139
CPD000466351
D00896
DB00625
DB07709
DMP 266
DMP-266
Du pont brand OF efavirenz
efavirenz
Efavirenz
|
Éfavirenz
Efavirenz (JAN/INN)
Efavirenz, (R)-isomer
efavirenz, (S)-isomer
Efavirenz, (S)-isomer
Efavirenzum
EFV
EFZ
Eravirenz
HMS2051J08
HMS2090N16
HSDB 7163
L 743726
L-741211
L-743,726
L-743725
L-743726
LS-173464
Merck sharp and dohme brand OF efavirenz
Met-SDF-1.beta. & Efavirenz
Met-Stromal Cell-derived Factor-1.beta. (Human) & Efavirenz
MLS000759465
MLS001424087
MolPort-003-983-924
NSC742403
SAM001246667
SBB066062
SMR000466351
Stocrin
Strocin (TM)
Sustiva
Sustiva (TM)
Sustiva (TN)
UNII-JE6H2O27P8
United drug brand OF efavirenz
ZINC02020233
zoxazin-2-one
|
|
| 7 |
|
Oxaliplatin |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1 |
|
61825-94-3 |
43805
6857599
5310940
9887054
|
|
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
Oxalatoplatinum
|
oxaliplatin
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
oxaliplatine
oxaliplatino
Oxaliplatino [Spanish]
oxaliplatinum
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
|
|
| 8 |
|
Bevacizumab |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 |
|
216974-75-3 |
|
|
Synonyms:
216974-75-3
antiVEGF
anti-VEGF monoclonal antibody
Avastin
Avastin (TN)
bevacizumab
|
Bevacizumab
Bevacizumab (genetical recombination)
Bevacizumab (genetical recombination) (JAN)
bevacizumab-awwb
D06409
R-435
|
|
| 9 |
|
Mechlorethamine |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
51-75-2 |
4033
|
|
Synonyms:
.Beta.,.beta.'-Dichlorodiethyl-N-methylamine
1, 5-Dichloro-3-methyl-3-azapentane hydrochloride
126-85-2 (N-oxide)
2,2'-Dichlorodiethyl-methylamine
2,2'-Dichloro-N-me
2,2'-dichloro-N-methyldiethylamine
2,2'-dichloro-N-Methyldiethylamine
2,2'-Dichloro-N-methyldiethylamine
2-Chloro-N-(2-chloroethyl)-N-methylethanamine
302-70-5 (N-oxide, hydrochloride)
51-75-2
55-86-7 (HYDROCHLORIDE)
AC1L1H9H
Antimit
b,Beta'-dichlorodiethyl-N-methylamine
beta,beta'-Dichlorodiethyl-N-methylamine
beta,Beta'-dichlorodiethyl-N-methylamine
Bis(2-chloroethyl)methylamine
Bis(b-chloroethyl)methylamine
Bis(beta-chloroethyl) methylamine
Bis(beta-chloroethyl)methylamine
Bis(β-chloroethyl)methylamine
BRN 0605323
BSPBio_001947
C07115
C5H11Cl2N
Carolysine
Caryolysin
Caryolysine
CCRIS 447
CHEBI:28925
CHEMBL427
Chloramine (the nitrogen mustard)
Chlorethazine
Chlormethine
Chlormethine (INN)
Chlormethine [INN:BAN]
Chlormethinum [INN-Latin]
CID4033
Cloramin
Clormetina
Clormetina [INN-Spanish]
D07671
DB00888
Di(2-chloroethyl)methylamine
Dichlor amine
Dichloren
DivK1c_000759
EINECS 200-120-5
Embechine
Embichin
ENT-25294
HMS1920J15
HMS2091B04
HMS502F21
HN2
HN-2
HSDB 5083
Hydrochloride N-oxide, mechlorethamine
Hydrochloride, mechlorethamine
I14-8708
IBS-L0033631
IDI1_000759
KBio1_000759
KBio2_001369
KBio2_003937
KBio2_006505
KBio3_001447
KBioGR_001448
KBioSS_001369
LS-7559
MBA
Me chloroethamine
Mebichloramine
mechlorethamine
|
Mechlorethamine
Mechlorethamine hydrochloride
Mechlorethamine hydrochloride N oxide
Mechlorethamine hydrochloride N-oxide
Mechlorethamine N oxide
Mechlorethamine N-oxide
Mechlorethamine oxide
Mechlorethanamine
Mechloroethamine
Mecloretamina
Mecloretamina [Italian]
Merck brand OF mechlorethamine hydrochloride
Merck frosst brand OF mechlorethamine hydrochloride
Methylbis(2-chloroethyl)amine
Methylbis(b-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Methylbis(β-chloroethyl)amine
Methylchlorethamine
Methyldi(2-chloroethyl)amine
Mitomen
Mitoxine (*Hydrochloride*)
MolPort-001-785-592
Mustargen
Mustine
Mustine note
Mutagen
N,N-Bis(2-chloroethyl)methylamine
N,N-Bis(2-chloroethyl)-N-methylamine
N,N-Di(chloroethyl)methylamine
NCGC00091835-02
NCGC00091835-03
NCGC00091835-04
NCGC00091835-05
NCI60_041682
NINDS_000759
Nitol (*Hydrochloride*)
Nitrogen mustard
Nitrogen mustard (HN-2)
Nitrogen mustard N oxide
Nitrogen mustard N-oxide
Nitrogranulogen
Nitromin
N-Lost
N-Methyl lost
N-Methyl-2,2'-dichlorodiethylamine
N-methyl-bis(2-chloroethyl)amine
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(b-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-Methyl-bis(β-chloroethyl)amine
N-Methyl-bis-chloraethylamin
N-Methyl-bis-chloraethylamin [German]
N-Methyl-lost
N-Methyl-lost [German]
N-Oxide, mechlorethamine hydrochloride
N-Oxide, nitrogen mustard
NSC 762
NSC762
NSC-762
SPBio_000496
Spectrum_000889
SPECTRUM1500375
Spectrum2_000448
Spectrum3_000484
Spectrum4_000924
Spectrum5_001702
Stickstofflost (*Hydrochloride*)
Stickstofflost (ebewe)
T 1024
T-1024
thyldiethylamine
TL 146
UNII-50D9XSG0VR
β,beta'-dichlorodiethyl-N-methylamine
β,β'-dichlorodiethyl-N-methylamine
|
|
| 10 |
|
Ifosfamide |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
3778-73-2 |
3690
|
|
Synonyms:
(+-)-Ifosfamid
(+-)-Ifosphamide
(+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
(D,L)-Ifosfamide
(R,S)-Ifosphamide
(R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
{3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd
2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI)
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
3,} 2-oxazaphosphorine oxide
36341-88-5
3778-73-2
84711-20-6
A 4942
AB00513932
AC1L1GHW
AC-2113
Ambap3778-73-2
Asta Z 4942
ASTA Z 4942
BPBio1_000865
BRN 0611835
BSPBio_000785
C07047
CAS-3778-73-2
CCRIS 352
CHEBI:5864
CHEMBL1024
CID3690
Cyfos
D00343
D007069
DB01181
EINECS 223-237-3
HMS1570H07
HMS2090M12
HMS2093N07
Holoxan
Holoxan 1000
HSDB 7023
I06-0494
Ifex
IFEX (TN)
Ifosfamid
Ifosfamida
Ifosfamida [INN-Spanish]
ifosfamide
Ifosfamide (JAN/USP/INN)
Ifosfamide [USAN:INN:BAN:JAN]
Ifosfamide sterile
|
Ifosfamide Sterile
Ifosfamidum
Ifosfamidum [INN-Latin]
Ifosphamide
Ifsofamide
Iphosphamid
Iphosphamid(e)
Iphosphamide
I-phosphamide
I-Phosphamide
iso Endoxan
Iso Endoxan
iso-Endoxan
Isoendoxan
Iso-Endoxan
Isofosfamide
Isophosphamide
isosfamide
Isosfamide
LS-102
LS-99799
Mitoxana
Mitoxana, Ifex, Ifosfamide
MJF 9325
MJF-9325
MLS002154021
MolPort-003-666-704
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide
N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine
N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide
Naxamide
NCGC00016639-01
NCGC00179435-01
NCI60_000233
NCI-C01638
NPFAPI-04
NSC 109,724
NSC 109724
NSC109,724
NSC-109,724
NSC109724
NSC-109724
Prestwick0_000833
Prestwick1_000833
Prestwick2_000833
Prestwick3_000833
S1302_Selleck
SMR001233348
SPBio_002706
STL058690
UNII-UM20QQM95Y
WLN: T6NPOTJ AM2G BO B2G
Z 4942
Z4942
Z-4942
|
|
| 11 |
|
Lamivudine |
Approved, Investigational |
Phase 4,Phase 2,Phase 3,Not Applicable |
|
134678-17-4 |
60825
|
|
Synonyms:
(-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine
(-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
(-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-2'-Deoxy-3'-thiacytidine
(-)-BCH 189
(-)-BCH-189
(-)-beta-L-2',3'-Dideoxy-3'-thiacytidine
(-)NGPB-21
(-)-SddC
(+/-) (Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(+/-)-3TC
(+/-)-BCH-189
(+/-)-SddC
(2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
.beta.-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To
134678-17-4
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Galanthus Nivalis Agglutinin (GNA)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Hippeastrum hybrid agglutinin( HHA)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-) (Cis)
2',3' Dideoxy 3' thiacytidine
2',3'-Dideoxy-3'-thiacytidine
3TC
3TC & GNA
3TC & SST
3TC (AIDS INITIATIVE) (AIDS INITIATIVE)
3TC and NV-01
3TC, Zeffix, Heptovir, Epivir, Epivir-HBV, Lamivudine
3'-Thia-2',3'-dideoxycytidine
480434-79-5
4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
AC-1416
AC1L1TZZ
AC1Q6C34
BCH 189
BCH189
BCH-189
BCH-790
beta-L-2',3'-Dideoxy-3'-thiacytidine
beta-L-3'-Thia-2',3'-dideoxycytidine
BIDD:GT0033
Bio-0652
b-L-2',3'-Dideoxy-3'-thiacytidine
b-L-3'-Thia-2',3'-dideoxycytidine
C07065
C8H11N3O3S
CCRIS 9274
CHEBI:133986
CHEMBL141
CID60825
CPD000466319
D00353
D019259
|
DB00709
DRG-0126
DTHC
Epivir
Epivir (TN)
Epivir(TM)
Epivir-HBV
Epzicom
FT-0082667
GG-714
GR 109714X
GR109714X
GR-109714X
Hepitec
Heptivir
Heptodin
Heptovir
HHA & 3TC
HHA & Lamivudine
HMS2051D21
HSDB 7155
L0217
Lamivir
Lamivudin
Lamivudina
lamivudine
Lamivudine
Lamivudine & GNA
Lamivudine (JAN/USP/INN)
Lamivudine [Usan:Ban:Inn]
Lamivudine [USAN:BAN:INN]
Lamivudine [USAN:INN:BAN]
Lamivudine, (2S-cis)-isomer
Lamivudine, (2S-cis)-Isomer
Lamivudinum
LMV
LS-2107
MLS000759424
MLS001424097
MolPort-002-507-347
NCGC00159341-03
NCGC00159341-04
NSC620753
S1706_Selleck
SAM001246582
SAM002589994
SMR000466319
STK801940
UNII-2T8Q726O95
Zeffix
Zefix
ZINC00012346
β-L-2',3'-dideoxy-3'-thiacytidine
β-L-3'-thia-2',3'-dideoxycytidine
|
|
| 12 |
|
Nevirapine |
Approved |
Phase 4,Phase 3 |
|
129618-40-2 |
4463
|
|
Synonyms:
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody)
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one
11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one
11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE
129618-40-2
1vrt
2hny
AC1L1I81
AC-643
BI RG 587
BIDD:GT0326
Bio-0789
BIRG 0587
BIRG 587
BIRG-0587
BIRG587
BIRG-587
BI-RG-587
BI-RG-587 & CD4-IgG
C07263
C15H14N4O
Cahill May Roberts Brand of Nevirapine
CHEBI:44659
CHEMBL57
CID4463
CPD000048458
D00435
D019829
DB00238
DB08311
Hemihydrate, nevirapine
HMS2051J09
|
HSDB 7164
I02-0310
LS-2289
MLS000084585
MLS000759409
MLS001055309
MLS001201730
MolPort-002-507-817
N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin
NCGC00065890-02
NEV
nevirapine
Nevirapine & CD4-IgG
Nevirapine & PRO 140
Nevirapine (JAN/USP/INN)
Nevirapine [USAN:INN]
Nevirapine anhydrous
Nevirapine hemihydrate
Nevirapine, anhydrous
NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE
NSC 641530
NSC641530
NVP
Promeco Brand of Nevirapine
S1742_Selleck
SAM001246551
SMR000048458
STK580320
UNII-99DK7FVK1H
Viramune
Viramune (TN)
Viramune(TM)
Viramune, BI-RG 587, Nevirapine
ZINC00004778
|
|
| 13 |
|
Stavudine |
Approved, Investigational |
Phase 4 |
|
3056-17-5 |
18283
|
|
Synonyms:
1-(2,3-Dideoxy-b-D-glycero-pent-2-enofuranosyl)thymine
1-(2,3-Dideoxy-beta-D-glycero-2-pentenofuranosyl)thymine
1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine
1-(2,3-Dideoxy-β-D-glycero-pent-2-enofuranosyl)thymine
1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione
1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione
1-[5-(hydroxymethyl)-2,5-dihydro-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione & Colony-stimulating factor 2
132425-31-1
2',3' didehydro 3' Deoxythymidine
2',3' Didehydro 3' deoxythymidine
2',3'-Anhydrothymidine
2',3'-didehydro-2',3'-Dideoxythmidine
2',3'-Didehydro-2',3'-dideoxythmidine
2',3'-didehydro-3'-Deoxythimidine
2',3'-Didehydro-3'-deoxythimidine
2',3'-didehydro-3'-Deoxythymidine
2',3'-Didehydro-3'-deoxythymidine
2',3'-DIDEHYDRO-3'-DEOXYTHYMIDINE (DDI)
3'- Azido-3'-deoxythymidine & Granulocyte-macrophage colony-stimulating factor
3056-17-5
3'-Deoxy-2',3'-didehydrothymidine
3'-Deoxy-2'-thymidinene
AC1L2BQ9
AC1Q6BSH
AC-5263
BB_NC-1008
BIDD:GT0082
BMY 27857
BMY27857
BMY-27857
Bristol-myers brand OF stavudine
Bristol-Myers Brand of Stavudine
Bristol-myers squibb brand OF stavudine
Bristol-Myers Squibb Brand of Stavudine
BRN 0618327
C07312
CHEBI:207119
CHEMBL991
CID18283
CPD000058350
CPD000673569
D 1413
D 4T
D 4T (nucleoside)
D00445
D018119
D1413_SIGMA
D3580
d4T
D4T & GM-CSF
D4TMBY-27857-3
DB00649
ddeThd
ddeTyd
|
Dideoxydidehydrothymidine
Estavudina
Estavudina [INN-Spanish]
EU-0100336
FT-0082665
HMS2051O20
HSDB 7338
Lopac0_000336
LS-1160
MLS000028546
MLS000759504
MLS001055348
MLS001077292
MolPort-002-507-283
NCGC00023212-03
NCGC00023212-04
NCGC00023212-05
NCGC00023212-07
NCGC00023212-08
NCGC00023212-09
NCGC00023212-10
NSC 163661
NSC163661
SAM001246729
SAM002589948
sanilvudine
Sanilvudine
Sanilvudine (JAN)
SMR000058350
SMR000673569
Stavudin
stavudine
Stavudine
Stavudine (USAN/INN)
Stavudine [Usan:Ban:Inn]
Stavudine [USAN:BAN:INN]
Stavudine [USAN:INN:BAN]
Stavudine, monosodium salt
Stavudine, Monosodium Salt
Stavudinum
Stavudinum [INN-Latin]
STK801888
STV
Thymine, 1-(2,3-dideoxy-beta-D-glycero-pent-2-enofuranosyl)- (7CI,8CI)
UNII-BO9LE4QFZF
Zent
Zerit
Zerit (TN)
Zerit Xr
Zerit XR
Zerit(TM)
Zerut XR
ZINC00137884
|
|
| 14 |
|
Emtricitabine |
Approved, Investigational |
Phase 4,Phase 3,Not Applicable |
|
143491-57-0 |
60877
|
|
Synonyms:
(-)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(−)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-(2R,5S)-5-fluoro-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-.beta.-L-FTC
(-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(−)-2'-deoxy-5-fluoro-3'-thiacytidine
(-)-2'-Deoxy-5-fluoro-3'-thiacytidine
(-)-b-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine
(-)-beta-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
(−)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
(-)-cis-4-amino-5-fluoro-1-(2-Hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
(-)-FTC
(−)-FTC
(-)-β-2',3'-dideoxy-5-fluoro-3'-thiacytidine
(−)-β-2',3'-dideoxy-5-fluoro-3'-thiacytidine
(2R-cis)-4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
(2R-cis)-4-amino-5-fluoro-1-(2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
(2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
.beta.-L-(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
1-(2-(Hydroxymethyl)oxathiolan-5-yl)-5-fluorocytosine
143491-54-7
143491-57-0
145213-48-5
2',3',5-FTC
2',3'-Dideoxy-5-fluoro-3'-thiacytidine
2'-Deoxy-5-fluoro-3'-oxa-4'-thiocytidine
2'-Deoxy-5-fluoro-3'-thiacytidine
2-FTC
3'-Thia-2'.3'-dideoxy-5-fluorocytidine
4-amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one
4-amino-5-fluoro-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one
4-amino-5-fluoro-1-((2R,5S)-2-Hydroxymethyl-[1,3]oxathiolan-5-yl)-1H-pyrimidin-2-one
4-Amino-5-fluoro-1-((2R,5S)-2-hydroxymethyl-[1,3]oxathiolan-5-yl)-1H-pyrimidin-2-one
4-Amino-5-fluoro-1-[(2R,5S)-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone
4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one
4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
524W91
5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
5-fluoro-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
|
5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)[1,3]oxathiolan-5-yl]cytosine
AC1L1U3I
AC1Q4KUB
beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine
BW 1592
BW 524W91
BW524W91
BW-524W91
C122114
C12599
C8H10FN3O3S
CHEBI:31536
CHEMBL885
CID60877
Coviracil
Coviracil(TM)
D01199
DB00879
dOTFC
DRG-0208
Emtricitabin
Emtricitabina
Emtricitabine
Emtricitabine (JAN/USAN/INN)
Emtricitabinum
Emtriva
Emtriva (TN)
Emtriva(TM)
FT-0080009
HMS2089I05
HSDB 7337
LS-135838
LS-173184
NCGC00164564-01
Racivir
RCV
SBB066061
TL8000958
UNII-G70B4ETF4S
ZINC03629271
|
|
| 15 |
|
Lopinavir |
Approved |
Phase 4,Phase 2,Phase 3 |
|
192725-17-0 |
92727
|
|
Synonyms:
(1S-(1R*(R*),3R*,4R*))-N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide
(2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
(alphaS)-Tetrahydro-N-((alphaS)-alpha-((2S,3S)-2-hydroxy-4-phenyl-3-(2-(2,6-xylyloxy)acetamido)butyl)phenethyl)-alpha-isopropyl-2-oxo-1(2H)-pyrimidineacetamide
1(2H)-Pyrimidineacetamide, N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, (alphaS)- (9CI)
192725-17-0
1mui
2o4s
2q5k
2rkf
2rkg
378, ABT
A 157378
A 157378.0
A-157378.0
A-157378-0
AB1
ABT 157378
ABT 378
ABT-378
ABT-378, LOPINAVIR
ABT-378a-157378-0a-157378.0
AC1L3OPJ
AIDS032937
Aluviran
|
C12871
C37H48N4O5
CHEBI:40456
CHEMBL729
CID92727
D01425
DB01601
Kaletra
Koletra
Lopinavir
Lopinavir (JAN/USAN/INN)
Lopinavir [USAN:INN:BAN]
LPV
LS-173766
MolPort-003-848-410
N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide
N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide
N-{1-BENZYL-4-[2-(2,6-DIMETHYL-PHENOXY)-ACETYLAMINO]-3-HYDROXY-5-PHENYL-PENTYL}-3-METHYL-2-(2-OXO-TETRAHYDRO-PYRIMIDIN-1-YL)-BUTYRAMIDE
NCGC00164576-01
NCGC00164576-02
RS-346
S1380_Selleck
UNII-2494G1JF75
|
|
| 16 |
|
Capecitabine |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1 |
|
154361-50-9 |
60953
|
|
Synonyms:
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
Capecitabin
capecitabina
Capecitabina
capecitabine
CAPECITABINE
Capécitabine
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
capecitabinum
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
CHEBI:31348
CHEMBL1773
CID60953
D01223
|
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
R340
R-340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
|
|
| 17 |
|
Aprepitant |
Approved, Investigational |
Phase 4,Phase 2,Not Applicable |
|
170729-80-3 |
6918365
151165
|
|
Synonyms:
(1-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-3-(fluoro)phenyl-4-(3-oxo-1,2,4-triazol-5-yl)methylmorpholine
(2R)-(1R)-3,5-Bis(trifluoromethylphenyl)ethoxy)-(3S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazole)methyl-morpholine
170729-80-3
221350-96-5
3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-Delta(2)-1,2,4-triazolin-5-one
3-(((2R,3S)-3-(P-Fluorophenyl)-2-(((alphar)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(2)-1,2,4-triazolin-5-one
3-(((2R,3S)-3-(P-Fluorophenyl)-2-(((alphar)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-Delta(2)-1,2,4-triazolin-5-one
3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(sup 2)-1,2,4-triazolin-5-one
3-(((2R,3S)-3-(P-Fluorophenyl)-2-(((alphar)-a-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(2)-1,2,4-triazolin-5-one
3-(((2R,3S)-3-(P-Fluorophenyl)-2-(((alphar)-a-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-δ(2)-1,2,4-triazolin-5-one
3-(((2R,3S)-3-(P-Fluorophenyl)-2-(((alphar)-α-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-δ(2)-1,2,4-triazolin-5-one
5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one
5-[[(2S,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one
5-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-one
AC1L45SL
AC1OCFCG
Aprepitant
Aprépitant
Aprepitant (JAN/USAN/INN)
Aprepitant [USAN]
Aprepitantum
CHEBI:323967
CHEBI:499361
CHEMBL135613
CHEMBL1471
CHEMBL249465
|
CID11214788
CID11318675
CID151165
CID6918365
CID9936947
CID9936948
D02968
DB00673
Emend
Emend (TN)
HMS2090N12
I06-1151
L 754030
L-754030
LS-156477
MK 0869
MK 869
MK-0517
MK-0869
MK-869
MK-869, L-754030, Emend, Aprepitant
MolPort-006-392-367
NCGC00181785-01
ONO-7436
S1189_Selleck
UNII-1NF15YR6UY
|
|
| 18 |
|
Fosaprepitant |
Approved |
Phase 4,Phase 2,Not Applicable |
|
172673-20-0 |
219090
|
|
Synonyms:
Emend for injection
Fosaprépitant
Fosaprepitant dimeglumine
|
Fosaprepitantum
L-758,298
L-758298
|
|
| 19 |
|
Lithium carbonate |
Approved |
Phase 4,Not Applicable |
|
554-13-2 |
|
|
Synonyms:
Carbonic acid, dilithium salt
Dilithium carbonate
|
Lithii carbonas
Lithonate
|
|
| 20 |
|
Enoxaparin |
Approved |
Phase 4,Not Applicable |
|
9005-49-6 |
772
|
|
Synonyms:
2-o-sulfohexopyranuronosyl-(1->4)-2-deoxy-3-o-sulfo-2-(sulfoamino)hexopyranosyl-(1->4)-2-o-sulfohexopyranuronosyl-(1->4)-2-acetamido-2-deoxy-6-o-sulfohexopyranose
6-[6-[6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-2-carboxy-4-hydroxy-5-sulfooxyoxan-3-yl]oxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid
AC1L19ZN
AR-1E4539
CID772
Clexane
D006495
D017984
DB00407
DB01225
EMT 966
EMT 967
EMT966
EMT-966
EMT967
EMT-967
|
enoxaparin
Enoxaparin sodium
Enoxaparine
Heparin, Low Molecular Weight
Heparin, Low-Molecular-Weight
LMWH
Lovenox
Lovenox HP
Low molecular weight heparin
Low molecular weight heparin sodium
Low-Molecular-Weight Heparin
PK 10,169
PK10,169
PK-10,169
PK10169
PK-10169
|
|
| 21 |
|
Heparin |
Approved, Investigational |
Phase 4,Phase 1,Not Applicable |
|
9005-49-6 |
772
46507594
|
|
Synonyms:
101921-26-0
102785-31-9
102-94-3
104521-37-1
11078-24-3
11129-39-8
12656-11-0
37324-73-5
9041-08-1
9045-22-1
9075-96-1
913079-23-9
91449-79-5
AC1L1ROY
ALFA 87-120
ALFA 87-163
ALFA 87-198
ALFA 87-81
ALFA 88-247
Allocinnamic acid
alpha-Heparin
Alpha-Heparin
Ardeparin
Ardeparin sodium
Ariven
Arteven
Bemiparin
Bemiparin sodium
Calcilean
Calciparine
Certoparin
CID8784
cis-.beta.-Carboxystyrene
cis-Cinnamic acid
Clexane
Clivarin
Clivarine
CY 216
Cy 222
Dalteparin
Dalteparin sodium
Depo-Heparin
EINECS 232-681-7
Enoxaparin
Enoxaparin sodium
Eparina
Eparina [DCIT]
Fluxum
FR 860
Fragmin A
Fragmin B
Fragmin IV
Fraxiparin
H 2149
Hed-heparin
Hed-Heparin
Hep Flush Kit in plastic container
Hepalean
heparin
Heparin Cy 216
Heparin CY 216
Heparin Leo
Heparin Lock Flush
Heparin Lock Flush in plastic container
Heparin Lock Flush preservative free
Heparin Lock Flush preservative free in plastic container
Heparin natrium
Heparin sodium
Heparin sodium 1,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 1,000 units in dextrose 5% in plastic container
Heparin sodium 1,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 10,000 units in dextrose 5%
Heparin sodium 10,000 units in dextrose 5% in plastic container
Heparin sodium 10,000 units in sodium chloride 0.45%
Heparin sodium 10,000 units in sodium chloride 0.9%
Heparin sodium 12,500 units in dextrose 5%
Heparin sodium 12,500 units in dextrose 5% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.45% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.9%
Heparin sodium 2,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 2,000 units in dextrose 5% in plastic container
Heparin sodium 2,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 20,000 units and dextrose 5% in plastic container
Heparin sodium 20,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units and dextrose 5% in plastic container
Heparin sodium 25,000 units in dextrose 5%
|
Heparin sodium 25,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.45% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.9%
Heparin sodium 25,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units in dextrose 5% in plastic container
Heparin sodium 5,000 units in sodium chloride 0.45%
Heparin sodium 5,000 units in sodium chloride 0.9%
Heparin sodium 5,000 units in sodium chloride 0.9% in plastic container
Heparin sodium in plastic container
Heparin sodium preservative Free
Heparin sodium salt
Heparin sulfate
Heparin sulphate
Heparin, sodium salt
heparina
Heparina
Heparina [INN-Spanish]
Heparinate
Heparine
Heparine [INN-French]
Heparinic acid
Heparinsodiumsalt
Heparinum
Heparinum [INN-Latin]
Heparinum natricum
Hepathrom
Hepflush-10
Hep-Lock
Hep-Lock U/P
HSDB 3094
Innohep
Inno-Hep
Isocinnamic acid
Kabi 2165
KB 101
Leparan
LHN 1
Lioton 1000
Lipo-hepin
Lipo-Hepin
Liquaemin
Liquaemin Lock Flush
Liquaemin Sodium
Liquaemin sodium preservative free
Liquemin
Logiparin
Low molecular weight heparin sodium
Minolteparin sodium
MolPort-003-760-257
Multiparin
Nadroparin
Nadroparine
Novoheparin
NSC174025
Octaparin
OP 386
OP 622
Pabyrin
Panheprin
Parnaparin
Parnaparin sodium
Parvoparin
Pularin
Reviparin
Reviparin sodium
Ro 11
Sandoparin
Sodium acid heparin
Sodium heparin
Sodium heparinate
Subeparin
Sublingula
Thromboliquine
Tinzaparin
Tinzaparin sodium
Triofiban
Unfractionated heparin
UNII-12M44VTJ7B
UNII-3S182ET3UA
UNII-E47C0NF7LV
UNII-T2410KM04A
UNII-ZZ45AB24CA
Vetren
Vitrum AB
WY 90493RD
|
|
| 22 |
|
Aspirin |
Approved, Vet_approved |
Phase 4,Phase 2,Not Applicable |
|
50-78-2 |
2244
|
|
Synonyms:
11126-35-5
11126-37-7
1oxr
2-(ACETYLOXY)benzoate
2-(ACETYLOXY)benzoIC ACID
2349-94-2
26914-13-6
2-Acetoxybenzenecarboxylate
2-Acetoxybenzenecarboxylic acid
2-Acetoxybenzoate
2-Acetoxybenzoic acid
2-Carboxyphenyl acetate
50-78-2
8-hour Bayer
98201-60-6
A 5376
A.S.A
A.S.A.
A.S.A. empirin
A.S.A. Empirin
A2093_SIGMA
A3160_SIGMA
A5376_SIGMA
A6810_SIGMA
AB1003266
AC 5230
AC1L1D8U
AC1Q1LA0
Acenterine
Acesal
Acetal
Acetard
Aceticyl
Acetilsalicilico
Acetilum acidulatum
Acetisal
Acetol
Acetonyl
Acetophen
Acetosal
Acetosalic acid
Acetosalin
Acetoxybenzoic acid
Acetylin
Acetylsal
Acetylsalicylate
Acetylsalicylic acid
ACETYLSALICYLIC ACID
Acetylsalicylsaeure
Acetylsalicylsaure
Acetylsalicylsäure
Acetylsalycilic acid
Acetyonyl
Acetysal
Acetysalicylic acid
Acid, acetylsalicylic
Acide 2-(acetyloxy)benzoique
acide 2-(acétyloxy)benzoïque
Acide acetylsalicylique
acide acétylsalicylique
acido Acetilsalicilico
Acido acetilsalicilico
ácido acetilsalicílico
Acido O-acetil-benzoico
Acidum acetylsalicylicum
Acimetten
Acisal
Acylpyrin
Adiro
AI3-02956
AIN
AKOS000118884
Aloxiprimum
ASA
Asacard
Asagran
Asatard
Ascoden-30
Aspalon
Aspec
Aspergum
Aspirdrops
aspirin
Aspirin
Aspirin (JP15/USP)
Aspirin [BAN:JAN]
Aspirina
Aspirina 03
Aspirine
Aspir-Mox
Asprin
Aspro
Aspro Clear
Asteric
Azetylsalizylsaeure
Azetylsalizylsäure
Bay-e-4465
Bayer
Bayer Aspirin 8 Hour
Bayer Buffered
Bayer Extra Strength Aspirin For Migraine Pain
Bayer Plus
Benaspir
Bialpirina
Bialpirinia
BIDD:GT0118
Bi-prin
BRN 0779271
Bufferin
C01405
Caprin
Cardioaspirin
Cardioaspirina
CCRIS 3243
Cemirit
CHEBI:15365
CHEMBL25
CID2244
Claradin
Clariprin
cMAP_000006
Colfarit
component of Midol
component of Synirin
Contrheuma retard
Coricidin
Crystar
D00109
D001241
DB00945
Decaten
Delgesic
Dispril
DivK1c_000555
Dolean pH 8
Duramax
Easprin
Easprin (TN)
ECM
Ecolen
Ecotrin
EINECS 200-064-1
Empirin
|
Empirin with Codeine
Endosprin
Endydol
Entericin
Enterophen
Enterosarein
Enterosarine
Entrophen
EU-0100038
Extren
Globentyl
Globoid
Helicon
HMS1920E13
HMS2090G03
HMS2091K13
HMS501L17
HSDB 652
I14-7505
IDI1_000555
Idragin
Istopirin
Kapsazal
KBio1_000555
KBio2_001725
KBio2_002271
KBio2_004293
KBio2_004839
KBio2_006861
KBio2_007407
KBio3_002149
KBio3_002751
KBioGR_000398
KBioGR_002271
KBioSS_001725
KBioSS_002272
Kyselina 2-acetoxybenzoova
Kyselina acetylsalicylova
Levius
Lopac0_000038
Lopac-A-5376
LS-143
Magnecyl
Measurin
Medisyl
Micristin
MLS001055329
MLS001066332
MLS001336045
MLS001336046
MolPort-000-871-622
NCGC00015067-01
NCGC00015067-04
NCGC00015067-09
NCGC00090977-01
NCGC00090977-02
NCGC00090977-03
NCGC00090977-04
NCGC00090977-05
NCGC00090977-06
NCGC00090977-07
nchem.859-comp6
NCI60_002222
Neuronika
NINDS_000555
Novid
NSC 27223
NSC27223
NSC406186
Nu-seals
Nu-seals aspirin
O-(Acetyloxy)benzoate
O-(Acetyloxy)benzoic acid
O-accetylsalicylic acid
O-Acetoxybenzoate
o-acetoxybenzoic acid
o-Acetoxybenzoic acid
O-Acetoxybenzoic acid
O-Acetylsalicylate
O-acetylsalicylic acid
O-Acetylsalicylic acid
o-carboxyphenyl acetate
o-Carboxyphenyl acetate
O-Carboxyphenyl acetate
O-Carboxyphenyl acetic acid
Persistin
Pharmacin
Pirseal
PL-2200
Polopirin
Polopiryna
Premaspin
R16CO5Y76E [UNII]
Rheumin tabletten
Rheumintabletten
Rhodine
Rhonal
Ronal
S-211
Salacetin
Salcetogen
Saletin
Salicylate acetate
salicylic acid acetate
Salicylic acid acetate
Salicylic acid acetic acid
Salicylic acid, acetate
Salospir
SMR000059138
Solfrin
Solprin
Solprin acid
Solpyron
Solupsan
SP 189
SPBio_001838
Spectrum_001245
SPECTRUM1500130
Spectrum2_001899
Spectrum3_001295
Spectrum4_000099
Spectrum5_000740
Spira-Dine
St. Joseph
St. Joseph Aspirin for Adults
ST075414
Supac
Tasprin
Temperal
Toldex
Triaminicin
Triple-sal
UNII R16CO5Y76E
UNII=R16CO5Y76E
UNII-R16CO5Y76E
UNM-0000306102
Vanquish
WLN: QVR BOV1
Xaxa
XAXA
Yasta
Zorprin
ZORprin
|
|
| 23 |
|
Dalteparin |
Approved |
Phase 4,Phase 1,Not Applicable |
|
9005-49-6 |
|
|
Synonyms:
|
| 24 |
|
Ethiodized oil |
Approved, Investigational |
Phase 4 |
|
8008-53-5 |
|
|
Synonyms:
|
| 25 |
|
Doxil |
Approved June 1999 |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
31703
|
|
Synonyms:
|
|
LipoDox
liposomal doxorubicin
Pegylated Liposomal Doxorubicin Hydrochloride
|
|
| 26 |
|
Tenofovir |
Experimental, Investigational |
Phase 4,Phase 3,Not Applicable |
|
147127-20-6 |
464205
|
|
Synonyms:
(R)-9-(2-Phosphonomethoxypropyl)adenine
(R)-9-(2-Phosphonylmethoxypropyl)adenine
(R)-PMPA
[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid
147127-20-6
206184-49-8
9-(2-Phosphonomethoxypropyl)adenine
9-(2-Phosphonylmethoxypropyl)adenine
9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer
9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098
9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer
9-PMPA (tenofovir)
AC1LA9BO
AC-760
Anh. tenofovir
Anhydrous tenofovir
Apropovir
CHEBI:45809
CHEMBL483
CID464205
D,L-Tenofovir
DB00300
Disoproxil fumarate, tenofovir
Disoproxil, tenofovir
Fumarate, tenofovir disoproxil
GNA & Tenofovir
|
GS 1275
GS 1278
GS1278
HHA & Tenofovir
KS-5021
MolPort-003-850-411
NCGC00167535-01
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Galanthus nivalis agglutinin (GNA)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Hippeastrum hybrid agglutinin( HHA)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- (9CI)
Phosphonic acid, [[2-(6-amino-9H-purin-9
PMPA
PMPA-(R)
S1401_Selleck
TDF
Tenefovir
Tenofovir
Tenofovir (anh.)
Tenofovir (anhydrous)
Tenofovir anhydrous
Tenofovir disoproxil
Tenofovir disoproxil fumarate
TFV
UNII-99YXE507IL
Viread
Viread, Tenofovir
|
|
| 27 |
|
Substance P |
Investigational |
Phase 4,Phase 2,Not Applicable |
|
33507-63-0 |
44359816
|
|
Synonyms:
Arg-pro-lys-pro-GLN-GLN-phe-phe-gly-leu-met-NH2
|
|
|
| 28 |
|
Antirheumatic Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 29 |
|
Anti-Bacterial Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 30 |
|
Immunologic Factors |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 31 |
|
Antineoplastic Agents, Alkylating |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 32 |
|
Alkylating Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 33 |
|
Antibiotics, Antitubercular |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 34 |
|
Topoisomerase Inhibitors |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 35 |
|
Immunosuppressive Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 36 |
|
Vaccines |
|
Phase 4,Phase 3,Phase 1,Phase 2 |
|
|
|
| 37 |
|
Anti-Retroviral Agents |
|
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 38 |
|
Nucleic Acid Synthesis Inhibitors |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 39 |
|
Antiviral Agents |
|
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 40 |
|
Anti-HIV Agents |
|
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 41 |
|
Anti-Infective Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 42 |
|
Antimetabolites |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 43 |
|
HIV Protease Inhibitors |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 44 |
|
protease inhibitors |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
|
Synonyms:
|
| 45 |
|
Cola |
|
Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable |
|
|
|
| 46 |
|
Angiogenesis Modulating Agents |
|
Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 |
|
|
|
| 47 |
|
Antimetabolites, Antineoplastic |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 48 |
|
Angiogenesis Inhibitors |
|
Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 |
|
|
|
| 49 |
|
Isophosphamide mustard |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
0
|
|
Synonyms:
Ifosfamide mustard
Ifosforamide mustard
IPAM
Iphosphoramide mustard
Isophosphamide mustard
Isophosphoramide mustard
|
N,N'-di-(2-chloroethyl)phosphorodiamidic acid
NN'-Bis-(2-chloroethyl)phosphate
NN'-Bis-(2-chloroethyl)phosphoric acid
Palifosfamide-tris
zio-201Isophosphamide mustard
|
|
| 50 |
|
Antiemetics |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 1892)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children |
Unknown status |
NCT00339118
|
Phase 4 |
doxorubicin, cytoxan |
| 2 |
Optimizing Influenza Vaccination in Surgical Oncology Patients |
Unknown status |
NCT01698177
|
Phase 4 |
|
| 3 |
HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT |
Completed |
NCT00380770
|
Phase 4 |
Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV |
| 4 |
Anti-Retrovirals for Kaposi's Sarcoma |
Completed |
NCT00444379
|
Phase 4 |
Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir |
| 5 |
Stereotactic Body Radiotherapy for Head and Neck Tumors |
Completed |
NCT01344356
|
Phase 4 |
|
| 6 |
OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum. |
Completed |
NCT00577031
|
Phase 4 |
bevacizumab [Avastin];Oxaliplatin;Xeloda |
| 7 |
Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) |
Completed |
NCT00552240
|
Phase 4 |
tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg |
| 8 |
Evaluation of Hyperbaric Oxygen Therapy on Wound Healing Following Management of Soft Tissue Sarcoma With Neo-Adjuvant Radiation and Surgical Resection |
Recruiting |
NCT03144206
|
Phase 4 |
Hyperbaric oxygen |
| 9 |
Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma |
Recruiting |
NCT03514381
|
Phase 4 |
Patients starting a treatment with Doxorubicin and Ifosfamide |
| 10 |
Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib |
Recruiting |
NCT03735758
|
Phase 4 |
Pazopanib or chemotherapy |
| 11 |
Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer |
Recruiting |
NCT02301962
|
Phase 4 |
Panitumumab |
| 12 |
Effects of a Neuroscience-based Technique on Post-traumatic Stress Disorder Symptoms, Inflammation, and Survival in Cancer Patients Announced of a Palliative Disease Progression and Their Partners |
Recruiting |
NCT03652298
|
Phase 4 |
|
| 13 |
Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma |
Recruiting |
NCT01669369
|
Phase 4 |
Lithium Carbonate;Placebo |
| 14 |
Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. |
Recruiting |
NCT02625389
|
Phase 4 |
Lipiodol® Ultra Fluid with surgical glues |
| 15 |
Low Molecular Weight Heparin (LMWH) vs Aspirin for Venous Thromboembolism (VTE) Prophylaxis in Orthopaedic Oncology |
Enrolling by invitation |
NCT03244020
|
Phase 4 |
Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe |
| 16 |
The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas |
Unknown status |
NCT00162721
|
Phase 3 |
doxorubicin, ifosfamide, cisplatin |
| 17 |
Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma |
Unknown status |
NCT00002516
|
Phase 3 |
cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate |
| 18 |
Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma |
Unknown status |
NCT01344018
|
Phase 3 |
|
| 19 |
Role of Barrier Resection in Local Control for Extremity Recurrent Soft Tissue Sarcomas |
Unknown status |
NCT02120768
|
Phase 3 |
|
| 20 |
Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma |
Unknown status |
NCT00334854
|
Phase 3 |
doxorubicin hydrochloride;ifosfamide |
| 21 |
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma |
Unknown status |
NCT00020566
|
Phase 3 |
busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate |
| 22 |
A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma |
Unknown status |
NCT00002318
|
Phase 3 |
Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride |
| 23 |
Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma |
Unknown status |
NCT00379457
|
Phase 3 |
carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate |
| 24 |
High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma |
Unknown status |
NCT00354744
|
Phase 3 |
cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate |
| 25 |
I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations |
Unknown status |
NCT02818725
|
Phase 3 |
Chemotherapy;panitumumab |
| 26 |
TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial |
Unknown status |
NCT02060006
|
Phase 3 |
Meloxicam 7.5mg daily for 8 weeks |
| 27 |
Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer |
Unknown status |
NCT01087268
|
Phase 3 |
|
| 28 |
Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor |
Unknown status |
NCT00685828
|
Phase 3 |
imatinib mesylate |
| 29 |
A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma |
Unknown status |
NCT02099396
|
Phase 2, Phase 3 |
Docetaxel+lobaplatin;Gemcitabine+lobaplatin |
| 30 |
Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma |
Unknown status |
NCT00691236
|
Phase 2, Phase 3 |
Zoledronic acid;Standard chemotherapy |
| 31 |
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma |
Unknown status |
NCT00075582
|
Phase 3 |
dactinomycin;cyclophosphamide;vincristine sulfate |
| 32 |
A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma |
Completed |
NCT01440088
|
Phase 3 |
TH-302 in Combination with Doxorubicin;Doxorubicin |
| 33 |
A Prospective Randomized Trial of Pre-Operative IMRT+Surgery Versus Surgery Alone For Primary Retroperitoneal Sarcoma |
Completed |
NCT00131898
|
Phase 3 |
|
| 34 |
Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma |
Completed |
NCT00142571
|
Phase 3 |
Gemcitabine;Docetaxel |
| 35 |
Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor |
Completed |
NCT00006734
|
Phase 3 |
cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate |
| 36 |
Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma |
Completed |
NCT00002985
|
Phase 3 |
daunorubicin hydrochloride;pegylated liposomal doxorubicin hydrochloride |
| 37 |
Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy |
Completed |
NCT00753688
|
Phase 3 |
PAZOPANIB;Placebo |
| 38 |
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas |
Completed |
NCT02049905
|
Phase 3 |
Aldoxorubicin;Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide) |
| 39 |
Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma |
Completed |
NCT01327885
|
Phase 3 |
Eribulin mesylate 1.4 mg/m^2 intravenous;Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV |
| 40 |
An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS) |
Completed |
NCT00796120
|
Phase 3 |
Trabectedin;Doxorubicin;Ifosfamide |
| 41 |
Trial Comparing Trabectedin to the Best Supportive Care in Patients With Sarcoma |
Completed |
NCT02672527
|
Phase 3 |
Trabectedin;Dexamethasone |
| 42 |
Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma |
Completed |
NCT01168791
|
Phase 3 |
doxorubicin in combination with palifosfamide-tris;doxorubicin in combination with placebo |
| 43 |
Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma |
Completed |
NCT00003212
|
Phase 3 |
doxorubicin hydrochloride;ifosfamide |
| 44 |
Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma |
Completed |
NCT00061984
|
Phase 3 |
doxorubicin hydrochloride;ifosfamide |
| 45 |
Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis |
Completed |
NCT00091351
|
Phase 3 |
|
| 46 |
Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma |
Completed |
NCT00003052
|
Phase 3 |
doxorubicin hydrochloride;etoposide;ifosfamide |
| 47 |
A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe |
Completed |
NCT00834457
|
Phase 2, Phase 3 |
abacavir/3TC/zidovudine;abacavir /3TC plus ritonavir boosted lopinavir |
| 48 |
Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma |
Completed |
NCT00003350
|
Phase 3 |
paclitaxel;pegylated liposomal doxorubicin hydrochloride |
| 49 |
Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) |
Completed |
NCT00538239
|
Phase 3 |
ridaforolimus;Placebo |
| 50 |
A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma |
Completed |
NCT00002319
|
Phase 3 |
Doxorubicin hydrochloride (liposomal) |
Inferred drug relations via
UMLS
73
/
NDF-RT
51
:
|
